Emerging Market ETFs See Fourth Consecutive Week of Inflows
Traders plowed cash into exchange-traded funds that buy emerging market stocks for a fourth straight week as risk-apetite grew, turning flows this year positive for the first time since early April.
The $9.7 billion Avantis Emerging Markets Equity ETF recorded more than $1 billion in inflows last week, its biggest jump in new cash ever recorded. That accounted for over half of the inflows into US-listed emerging market ETFs that invest across developing nations, according to data compiled by Bloomberg.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
11 minutes ago
- Los Angeles Times
Musk touts driverless Tesla test ahead of Austin robotaxi launch
Tesla Inc. executives including Elon Musk promoted a video of one of its vehicles driving in Austin with nobody behind the wheel, hinting that it's close to launching its robotaxi service in the Texas capital. A black Model Y emblazoned with 'robotaxi' on its front door turned off South Congress Avenue in a touristy area of the city in the video, which was posted to Musk's social media platform X. Musk shared the video on his X account, as did Ashok Elluswamy, who leads Tesla's Autopilot teams and recently took over responsibility for the company's Optimus humanoid robot program. Although neither Musk nor Tesla have specified a precise launch date, Bloomberg has reported that Tesla aims to begin operating its robotaxi network on June 12. The company has been testing self-driving Model Y SUVs that will be used in the operation's initial phase. Model Ys with manufacturer plates and a person behind the wheel have been spotted driving around parts of Austin, including South Congress. The vehicles are expected to use an 'unsupervised' version of Tesla's suite of driver-assist systems known as Full Self-Driving. In a separate X post, Musk said the vehicle in the video was running on a new version of software. Musk has staked the future of his electric-vehicle company to robotics, autonomy and artificial intelligence. He's said the robotaxi launch in Austin will start small, with as few as ten to twenty vehicles, before growing over time. It's unclear who will be the first users of the robotaxi service, what app will be used or how much rides will cost. Carlson writes for Bloomberg.
Yahoo
14 minutes ago
- Yahoo
Fortive (NYSE:FTV) Reaffirms Q2 2025 Earnings Guidance of US$0.44-US$0.49 EPS
Fortive recently reaffirmed its earnings guidance for the second quarter of 2025, expecting diluted net earnings per share between $0.44 and $0.49. This stable outlook may have provided some support to their shares, which rose by 4% over the past week. This movement occurred amid broader market gains, aligning with the overall uptrend. As the market climbed 1.5% with anticipation around U.S.-China trade talks and corporate earnings, Fortive's performance seems to have echoed this positive sentiment. Meanwhile, external factors like rising indices may have outweighed any isolated company-specific developments. We've identified 1 warning sign with Fortive and understanding the impact should be part of your investment process. Find companies with promising cash flow potential yet trading below their fair value. The recent reaffirmation of Fortive's earnings guidance appears to have provided some confidence to investors, contributing to the 4% rise in its share price over the past week. This news aligns with broader market movements, as the market increased by 1.5% amid positive sentiments surrounding U.S.-China trade discussions and corporate earnings. Over the past five years, Fortive has achieved a total shareholder return of 38.83%, including both share price appreciation and dividends. This return provides a longer-term perspective, surpassing some expectations within the machinery industry, which had a 9.9% return over the past year, where Fortive underperformed. This latest guidance update may influence future revenue and earnings forecasts positively by reinforcing confidence in Fortive's stability. Analysts are keenly watching how Fortive's separation into New Fortive and Ralliant could unlock further value through targeted strategies. Given the current share price of US$67.25, just under the analyst consensus price target of US$82.86, the company's short-term rise offers a slight discount opportunity. The emphasis on recurring revenue streams and mitigating tariff impacts remains crucial for sustaining profit margins, as the company aims for revenue stability and improved earnings projections nearing US$1.4 billion by 2028. Fortive's ongoing initiatives are expected to impact revenue and margins as they progress towards these targets. The analysis detailed in our Fortive valuation report hints at an inflated share price compared to its estimated value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:FTV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
IQVIA Holdings (NYSE:IQV) Sees 11% Share Price Rise Over Last Week
IQVIA Holdings experienced a 10% rise in share price over the last week, correlating with its recent developments, notably the dosing of the first patient in the RENEW Phase 2 trial and its strategic alliance with Sarah Cannon Research Institute to optimize oncology trials. These initiatives likely provided a positive sentiment boost, aligning well with the broader market momentum, as indices such as the S&P 500 also reached new highs. The market's anticipation over US-China trade talks and overall strong corporate earnings have supported the upward trend, further enhancing IQV's market performance. We've identified 1 warning sign for IQVIA Holdings that you should be aware of. Uncover 18 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent 10% rise in IQVIA Holdings' share price has been influenced by important developments like the dosing in the RENEW Phase 2 trial and a key alliance with Sarah Cannon Research Institute. These initiatives are expected to potentially drive revenue growth, particularly as the strategic alliance optimizes oncology trials. The company's past performance, with total returns of 10.45% over five years, suggests modest growth in investor value. However, compared to the US Life Sciences industry's one-year return of 27% decline, IQVIA's recent rise highlights positive market sentiment. These initiatives, combined with FDA reforms and NVIDIA collaboration, may lower operational costs and have a favorable impact on earnings forecasts. Analysts predict revenue to grow by 5.2% annually over the next three years, which is somewhat cautious compared to the general expectations for the life sciences sector. The recent share price movement to US$146.2 remains below the consensus price target of US$216.31, indicating potential for future appreciation if the projected growth in revenue and earnings materializes. Click here to discover the nuances of IQVIA Holdings with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:IQV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
